Framingham, MA – According to filings with the U.S. Securities and Exchange Commission, Solace Therapeutics is raising $17,550,000.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, William Gruber played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Solace Therapeutics

Solace Therapeutics is an emerging women’s health company focused on a revolutionary non-surgical office based treatment for unexpected bladder leaks, the primary symptom of female Stress Urinary Incontinence (SUI). SUI, the most prevalent form of incontinence among women, affects an estimated 28 million adult women in the U.S.

To learn more about Solace Therapeutics, visit http://www.solacetx.com/

Contact:
William Gruber, President and Chief Executive Officer
508-283-1200
wgruber@solacetx.com
https://www.linkedin.com/in/billgruber1/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved